Next Generation Sequencing in Cancer Research, Volume 2: From Basepairs to Bedsides, the second in the series “Next Generation Sequencing Technology in Cancer Research—From Basepairs to Bedsides, ” is designed to fill the gap between cancer genome research and clinical management of the individual cancer patient. The volume presents the principles of next generation sequencing (NGS) technologies and massively parallel DNA sequencing and their application of the whole genome sequences (WGS), whole exome-seq (WES), RNA-seq, miRNA-seq, and ChIP-seq in cancer research programs and to apply the newly discovered driver genetic alterations for prevention, early diagnosis and genome-oriented precision cancer treatment. Next Generation Sequencing in Cancer Research, Volume 2: From Basepairs to Bedsides brings together the implementation of a wide range of NGS technologies, including single-cell sequencing, in the clinical setting: discovery and validation of cancer biomarkers, standardization of NGS data production, NGS data reporting systems for clinicians, novel anti-cancer therapies  development from NGS data, conducting of clinical trials of newly investigated cancer drugs. It provides compelling evidence to signal a new future for health care and a new standard for cancer care.